These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 25061799)

  • 1. Efficient synthesis of Empagliflozin, an inhibitor of SGLT-2, utilizing an AlCl3-promoted silane reduction of a β-glycopyranoside.
    Wang XJ; Zhang L; Byrne D; Nummy L; Weber D; Krishnamurthy D; Yee N; Senanayake CH
    Org Lett; 2014 Aug; 16(16):4090-3. PubMed ID: 25061799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis of empagliflozin, a novel and selective sodium-glucose co-transporter-2 inhibitor, labeled with carbon-14 and carbon-13.
    Hrapchak M; Latli B; Wang XJ; Lee H; Campbell S; Song JJ; Senanayake CH
    J Labelled Comp Radiopharm; 2014 Oct; 57(12):687-94. PubMed ID: 25332189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors.
    Grempler R; Thomas L; Eckhardt M; Himmelsbach F; Sauer A; Sharp DE; Bakker RA; Mark M; Klein T; Eickelmann P
    Diabetes Obes Metab; 2012 Jan; 14(1):83-90. PubMed ID: 21985634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Research progress of sodium-glucose co-transporter 2 inhibitors for treatment of type 2 diabetes].
    Wan HX; Shen JK
    Yao Xue Xue Bao; 2012 Jun; 47(6):716-24. PubMed ID: 22919717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a Scalable Synthesis of Tofogliflozin.
    Ohtake Y; Emura T; Nishimoto M; Takano K; Yamamoto K; Tsuchiya S; Yeu SY; Kito Y; Kimura N; Takeda S; Tsukazaki M; Murakata M; Sato T
    J Org Chem; 2016 Mar; 81(5):2148-53. PubMed ID: 26871504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ortho-Substituted C-aryl glucosides as highly potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors.
    Xu B; Feng Y; Lv B; Xu G; Zhang L; Du J; Peng K; Xu M; Dong J; Zhang W; Zhang T; Zhu L; Ding H; Sheng Z; Welihinda A; Seed B; Chen Y
    Bioorg Med Chem; 2010 Jun; 18(12):4422-32. PubMed ID: 20576578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and biological evaluation of novel C-aryl d-glucofuranosides as sodium-dependent glucose co-transporter 2 inhibitors.
    Lin TS; Liw YW; Song JS; Hsieh TC; Yeh HW; Hsu LC; Lin CJ; Wu SH; Liang PH
    Bioorg Med Chem; 2013 Nov; 21(21):6282-91. PubMed ID: 24071445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Empagliflozin (Jardiance) for diabetes.
    Med Lett Drugs Ther; 2014 Oct; 56(1453):99-100. PubMed ID: 25296258
    [No Abstract]   [Full Text] [Related]  

  • 9. The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db/db mice both as monotherapy and in combination with linagliptin.
    Kern M; Klöting N; Mark M; Mayoux E; Klein T; Blüher M
    Metabolism; 2016 Feb; 65(2):114-23. PubMed ID: 26773934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment.
    Macha S; Mattheus M; Halabi A; Pinnetti S; Woerle HJ; Broedl UC
    Diabetes Obes Metab; 2014 Mar; 16(3):215-22. PubMed ID: 23859488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and biological evaluation of novel tetrahydroisoquinoline-C-aryl glucosides as SGLT2 inhibitors for the treatment of type 2 diabetes.
    Pan X; Huan Y; Shen Z; Liu Z
    Eur J Med Chem; 2016 May; 114():89-100. PubMed ID: 26974378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and biological evaluation of novel dioxa-bicycle C-aryl glucosides as SGLT2 inhibitors.
    Yan Q; Ding N; Li Y
    Carbohydr Res; 2016 Feb; 421():1-8. PubMed ID: 26735747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and warfarin in healthy volunteers.
    Macha S; Rose P; Mattheus M; Pinnetti S; Woerle HJ
    Diabetes Obes Metab; 2013 Apr; 15(4):316-23. PubMed ID: 23094794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, coadministered with sitagliptin in healthy volunteers.
    Brand T; Macha S; Mattheus M; Pinnetti S; Woerle HJ
    Adv Ther; 2012 Oct; 29(10):889-99. PubMed ID: 23054692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel macrocyclic C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents.
    Kim MJ; Lee SH; Park SO; Kang H; Lee JS; Lee KN; Jung ME; Kim J; Lee J
    Bioorg Med Chem; 2011 Sep; 19(18):5468-79. PubMed ID: 21868239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of Ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus.
    Imamura M; Nakanishi K; Suzuki T; Ikegai K; Shiraki R; Ogiyama T; Murakami T; Kurosaki E; Noda A; Kobayashi Y; Yokota M; Koide T; Kosakai K; Ohkura Y; Takeuchi M; Tomiyama H; Ohta M
    Bioorg Med Chem; 2012 May; 20(10):3263-79. PubMed ID: 22507206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension.
    Gembardt F; Bartaun C; Jarzebska N; Mayoux E; Todorov VT; Hohenstein B; Hugo C
    Am J Physiol Renal Physiol; 2014 Aug; 307(3):F317-25. PubMed ID: 24944269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel thiophenyl C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents.
    Lee SH; Song KS; Kim JY; Kang M; Lee JS; Cho SH; Park HJ; Kim J; Lee J
    Bioorg Med Chem; 2011 Oct; 19(19):5813-32. PubMed ID: 21906953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. C-aryl glucosides substituted at the 4'-position as potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.
    Xu B; Feng Y; Cheng H; Song Y; Lv B; Wu Y; Wang C; Li S; Xu M; Du J; Peng K; Dong J; Zhang W; Zhang T; Zhu L; Ding H; Sheng Z; Welihinda A; Roberge JY; Seed B; Chen Y
    Bioorg Med Chem Lett; 2011 Aug; 21(15):4465-70. PubMed ID: 21737266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes.
    Heise T; Seewaldt-Becker E; Macha S; Hantel S; Pinnetti S; Seman L; Woerle HJ
    Diabetes Obes Metab; 2013 Jul; 15(7):613-21. PubMed ID: 23356556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.